June 29, 2022
June has been an exciting month for Scientific Education Support (SES), with fantastic activities and updates from a busy period of major hematology congresses.
The Partnerships team took the opportunity to attend ASCO in Chicago and EHA in Vienna and experienced some fantastic interactions with new and existing supporters. We were able to highlight key developments on the platforms and from the content coverage plans in the coming months, particularly regarding our hot topics abstract lists for the hubs.
We asked Senior Partnership Managers, Geoff Jones and Emma Williams, for their review and conclusions of these congresses.
“Attending EHA was a great opportunity and a first conference experience representing SES. Highlights were being able to meet with key supporters for the MM and MDS platforms in person and highlighting our great work in delivering upon the educational objectives of the platforms, particularly increasing knowledge of novel targets and mechanisms of action for agents within the therapy space. The learning opportunities from the scientific sessions were of excellent value, especially with the backdrop of a beautiful city like Vienna.” — Geoff Jones
“For my first congress experience representing SES, it was wonderful to finally meet so many key supporters and contacts. It provided the ideal opportunity discuss the expansion of our platforms, particularly in acute leukaemia and our focus on the topic of MRD and effectively utilizing next-generation sequencing to aid personalised treatment plans. I also took the opportunity to discuss some the exciting bespoke CME projects, which we are launching from July onwards. Having attended several sessions, I was left fascinated by the amazing innovation demonstrated within haematology.” — Emma Williams
The Partnerships team look forward to continuing our discussions as we move into the summer. The planning now begins for SES presence in New Orleans for the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in December.
We are delighted to confirm that Syndax will be continuing its support of the AML Hub. As a Bronze supporter, Syndax’s support will contribute towards enabling the team to meet the key educational objectives of the platform, including stating the best practice use of novel agents in AML.
We are delighted to announce that Thermo Fisher Scientific will be supporting the MDS Hub as a Bronze supporter. As a key supporter of the sister platform, AML Hub, we’re encouraged to see Thermo Fisher Scientific widen their existing support to this key learning resource for clinicians treating myelodysplastic syndromes. Thermo Fisher Scientific now join BMS and Janssen as key supporters of this platform.
We are pleased to welcome AstraZeneca to the supporter group of the Lymphoma Hub. As a key stakeholder within the treatment of CLL, we are delighted to have AstraZeneca joining the key industry stakeholders in providing support to the biggest platform within SES’s hematology franchise.
Bespoke educational opportunities
We are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms, we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to healthcare professionals.
CAR T-cell therapy: Cross-platform webinar series (Lymphoma, Multiple Myeloma, and ALL Hubs)
In a first for the hematology hubs, this series of webinars will address unmet educational needs pertaining to the growing scope of CAR T-cell therapies across the hematology indications. With consideration of the complex treatment journey from the initial consultation through to transition of care, this project aims to support healthcare professionals involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three hub platforms, the content will also remain on the platforms as a valuable source of enduring content.
Beyond JAK inhibition: Novel agents for the treatment of advanced myelofibrosis
This clinical trial club is a live webinar series where one of our steering committee members is joined by a guest author/lead investigator of a relevant publication/clinical trial. Clinical trial clubs effectively support healthcare professionals in understanding what the latest news means for clinical practice. They offer the ideal solution to address a key learning gap of “suboptimal knowledge of novel therapeutic targets in MPN.”
Sequencing of therapies in acute lymphoblastic leukemia (ALL)
This case-based symposium will discuss the issues linked with the sequencing of therapies for B- and T-cell ALL. A panel of selected ALL Hub key opinion leaders will discuss cases related to both types of the disease. Pre- and post-case discussion will help develop viewers’ understanding of the recommended treatment algorithm in these cases and viewer interactivity with the panel will help raise confidence and competence in their management of these diseases. We are seeking support from industry stakeholders to enable the delivery of this learning initiative.
Please contact the Partnerships team on email@example.com if you would like to learn more about supporting these educational initiatives.
Looking to receive the latest news, project updates, and new offerings?